Results 31 to 40 of about 12,743 (165)

Prediction of Mycobacterium tuberculosis pyrazinamidase function based on structural stability, physicochemical and geometrical descriptors.

PLoS ONE, 2020
BackgroundPyrazinamide is an important drug against the latent stage of tuberculosis and is used in both first- and second-line treatment regimens.
Rydberg Roman Supo-Escalante, Aldhair Médico, Eduardo Gushiken, Gustavo E Olivos-Ramírez, Yaneth Quispe, Fiorella Torres, Melissa Zamudio, Ricardo Antiparra, L Mario Amzel, Robert H Gilman, Patricia Sheen, Mirko Zimic   +11 more
doaj   +1 more source

Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure.

PLoS ONE, 2023
Tuberculosis stands as a prominent cause of mortality in developing countries. The treatment of tuberculosis involves a complex procedure requiring the administration of a panel of at least four antimicrobial drugs for the duration of six months.
Fizza Mushtaq, Syed Mohsin Raza, Adeel Ahmad, Hina Aslam, Atiqa Adeel, Sidrah Saleem, Irfan Ahmad   +6 more
doaj   +1 more source

Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment

Journal of Microbiology, Immunology and Infection, 2018
Background: Multidrug-resistant and extensively drug-resistant tuberculosis infections cause public health concerns worldwide. Local epidemiologic data about the drug resistance of Mycobacterium tuberculosis isolate (Mtb) is critical to guide appropriate
Cheng-Yu Kuo, Wen-Hung Wang, Chung-Hao Huang, Yen-Hsu Chen, Po-Liang Lu   +4 more
doaj   +1 more source

Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis [PDF]

Tuberculosis, 2009
Resistance of Mycobacterium tuberculosis to pyrazinamide is associated with mutations in the pncA gene, which codes for pyrazinamidase. The association between the enzymatic activity of mutated pyrazinamidases and the level of pyrazinamide resistance remains poorly understood. Twelve M.
Patricia, Sheen, Patricia, Ferrer, Robert H, Gilman, Jon, López-Llano, Patricia, Fuentes, Eddy, Valencia, Mirko J, Zimic   +6 more
openaire   +2 more sources

Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China [PDF]

Tuberculosis, 2016
Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, however, there are relatively few available data on PZA resistant (PZA-R) rate in China. From June 2009 to June 2012, we selected 493 isolates from five field settings in China to investigate PZA-R by pncA gene sequencing.
Peng, Xu, Jie, Wu, Chongguang, Yang, Tao, Luo, Xin, Shen, Yangyi, Zhang, Chijioke A, Nsofor, Guofeng, Zhu, Brigitte, Gicquel, Qian, Gao   +9 more
openaire   +2 more sources

Pyrazinoic Acid Inhibits the Bifunctional Enzyme (Rv2783) in Mycobacterium tuberculosis by Competing with tmRNA

Pathogens, 2019
Pyrazinamide (PZA) is a key drug for tuberculosis treatment. The active form of PZA, pyrazinoic acid (POA), appears to inhibit multiple targets in M. tuberculosis. Recently, the bifunctional enzyme Rv2783 was reported as a new target of POA. However, the
Lei He, Peng Cui, Wanliang Shi, Qiong Li, Wenhong Zhang, Min Li, Ying Zhang   +6 more
doaj   +1 more source

Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial

BMC Infectious Diseases, 2021
Background Multidrug-resistant tuberculosis (MDR-TB) are unsatisfied to treat, pressing more effective and innovative treatment regimens. New efficient regimens for MDR-TB have obtained high treatment success rates.
Taoping Weng, Feng Sun, Yang Li, Jiazhen Chen, Xinchang Chen, Rong Li, Shijia Ge, Yanlin Zhao, Wenhong Zhang   +8 more
doaj   +1 more source

Exploring of pyrazinamidase recombinant activity from PZA-sensitive and resistant Mycobacterium tuberculosis expressed in Escherichia coli BL21 (DE3) [PDF]

Brazilian Journal of Biology
The mutations of pncA gene encoding pyrazinamidase/PZase in Mycobacterium tuberculosis are often associated with pyrazinamide/PZA resistance. The H and R1 isolates showed significant phenotypic differences to PZA.
P. Purkan, S. Hadi, W. Retnowati, S. Sumarsih, D. K. Wahyuni, B. Piluharto, T. M. Panjaitan, C. Ifada, A. Nadila, B. A. Nabilah   +9 more
doaj   +1 more source

Insight to pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking [PDF]

Bioinformation, 2009
Pyrazinamide (PZA) - an important drug in the anti-tuberculosis therapy, activated by an enzyme Pyrazinamidase (PZase). The basis of PZA resistance in Mycobacterium tuberculosis was owing to mutation in pncA gene coding for PZase. Homology modeling of PZase was performed using software Discovery Studio (DS) 2.0 based on the crystal structure of the ...
Unissa, A N, Selvakumar, N, Hassan, S
openaire   +3 more sources

Pyrazinamide Resistance: A Major Cause of Switching Shorter to Longer Bedaquiline-based Regimens in Multidrug-resistant Tuberculosis Patients

International Journal of Mycobacteriology
Background: All-oral regimens, including bedaquiline, are now standard in shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB). Resistance or intolerance to drugs in STR often necessitates a switch to longer treatment regimens (
Oki Nugraha Putra, Nur Indah, Telly Purnamasari, Adi Larasanti   +3 more
doaj   +1 more source